Search
  • 网站搜寻
亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。
返回搜索结果

Use Of Antibiotic Peptides Produced By Human Corneal Epithelial Cells To Manage Infection


技术优势

Use of human recombinant peptide would minimize allergic reactions. By enhancing the killing and removal of bacterial pathogens from the eye, the antibacterial peptide or compounds that induceits expression would promote healing of ocular tissues damaged by the bacterial disease process.


技术应用

Topical application of the antibacterial peptide itself to human ocular tissues to treat an infection of the cornea, conjunctiva, or adnexa caused bysusceptible bacterial pathogTopical application of the antibacterial peptide, in combination with existing topical ocular antibacterial drugs, to the human eye to treat activeinfections of the cornea, conjunctiva, or adnexa caused by susceptible bacteria. Combination therapy minimizes resistance, and the peptide is likelyto be additive or even synergistic with aminoglycoside or Fluoroquinolone ocular antibacterial drugs.Topical application of a compound that induces increased expression of the antibacterial peptide in human ocular tissues to treat an activeinfection of the cornea, conjunctiva, or adnexa caused by susceptible bacterial pathogens. This approach causes the eye to use its own defensesystem. Bacterial resistance to the inducing compound would be unlikely since the inducer would not itself be antibacterial. Topical application of the antibacterial peptide and/or an inducer of the antibacterial peptide prophylactically, to human ocular tissues to preventan active infection of the cornea, conjunctiva, or lids in an individual deemed at risk of developing such an infection.


详细技术说明

None


附加资料

Patent Number: US6984622B2
Application Number: US2002121227A
Inventor: Fleiszig, Suzanne M. J. | McNamara, Nancy A.
Priority Date: 25 Mar 1998
Priority Number: US6984622B2
Application Date: 10 Apr 2002
Publication Date: 10 Jan 2006
IPC Current: A61K003800 | A61K003817 | G01N003368
US Class: 5140021 | 514002 | 5140094 | 5140208 | 514012
Assignee Applicant: The Regents of the University of California
Title: Use of lipopolysaccharides to manage corneal infections and wounds
Usefulness: Use of lipopolysaccharides to manage corneal infections and wounds
Summary: The antibiotic polypeptide hBD-2 is useful for preventing or treating cutaneous wounds affecting the epidermal and dermal layers of the skin, or ocular wounds, such as corneal wound or corneal infection caused by Pseudomonas aeruginosa or other pathogens. The hBD-2-stimulating compound is useful for upregulating the endogenous expression of hBD-2. The hBD-2 can be used as tear film supplements used in conjunction with contact lens wear preventing bacterial infection. The β-defensins can also be used as a component in the solutions used for storage and transfer of corneas prior to transplant.
Novelty: Use of a human beta defensin-2 polypeptide for preventing or treating cutaneous wounds or ocular wounds, such as corneal wound or corneal infection commonly caused by Pseudomonas aeruginosa


主要类别

诊断/治疗


细分类别

其他疾病


其他

Tech ID/UC Case

18550/1998-040-0


Related Cases

1998-040-0


国家/地区

美国

欲了解更多信息,请点击 这里
Business of IP Asia Forum
桌面版